A six-year-old South Korean biotech startup is carving out plans for the U.S. by establishing a subsidiary based in Cambridge.

The company, Genuv Inc., has been in the business of developing neurodegenerative disease drugs since 2016. Genuv’s lead drug candidate for amyotrophic lateral sclerosis, or ALS, is in a Phase 1/2a trial in Korea with data expected later this year. Meanwhile, the company has begun work on its next focus area: immuno-oncology.

 

Read more via the Boston Business Journal >>>